Neurocrine Biosciences (NBIX) is in focus after a strong first quarter of 2026 with higher revenue and net income, along with fresh CRENESSITY clinical data and new guidance on glucocorticoid dose reduction.

The recent run of strong news around CRENESSITY, new obesity programs and a very robust first quarter has coincided with building momentum in the stock, with a 30 day share price return of 20.88% and a 1 year total shareholder return of 33.31%.

If this kind of pipeline driven move has your attention, it could be a good moment to explore what else is developing in healthcare by checking out 33 healthcare AI stocks

With revenue and net income growing at double digit rates and the stock up 33.31% over the past year, plus an indicated 65% intrinsic discount, is Neurocrine still offering an entry point, or is the market already pricing in future growth?

Most Popular Narrative: 16.4% Undervalued

With Neurocrine Biosciences last closing at $155.80 against a narrative fair value of $186.45, the current price sits well below what this widely followed model estimates, putting the focus squarely on how INGREZZA and CRENESSITY shape the story from here.

Rapid and consistent early adoption of CRENESSITY, with demonstrated high rates of reimbursement (>75%), robust clinical profile, and significant unmet need in CAH, indicates the likelihood of future blockbuster status, driving both top-line revenue growth and improved operating leverage.

Curious what assumptions sit behind that fair value gap? The narrative leans on sustained revenue growth, rising margins, and a future earnings base that looks very different to today.

Result: Fair Value of $186.45 (UNDERVALUED)

However, there are still pressure points to watch, including potential pricing and reimbursement headwinds around INGREZZA and the concentration risk if key late stage programs disappoint.

Next Steps

Given the mix of optimism and caution so far, this is the point where you pressure test the story against the numbers yourself and not just the headlines. To see what is driving the optimistic view, take a closer look at the company's 4 key rewards

Looking for more investment ideas?

If Neurocrine has sharpened your focus, do not stop here. Let the same structured approach guide you toward other opportunities that might suit your goals.

• Target reliable income by reviewing companies built around strong cash distributions through the 13 dividend fortresses
• Spot potential value opportunities early by scanning companies that appear attractively priced using the 44 high quality undervalued stocks
• Prioritize resilience by focusing on companies with sturdy finances through the solid balance sheet and fundamentals stocks screener (46 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.